What do synthetic biology, machine learning and robotics have in common? James Field, CEO and founder of LabGenius, explains how his company is integrating bleeding-edge technologies from across these fields to discover the next-generation therapeutic antibodies. And change the way we approach drug discovery.
Find out more about Labgenius here and follow them on LinkedIn
Find Balderton Capital here and follow us on LinkedIn
